Weekly News Round-up – 1/5/20
3 years ago
By Josh Neil
This week, Covid-19 vaccines see some advancement, with remdesivir showing strong signs of success as Pfizer prepare to put their own candidate through U.S. trials starting from next week. In other news, ‘natural killer’ cell therapies show strong potential efficacy in fighting cancers as the next big cell therapy, and GSK announces that almost all non-Covid-related drug trials have been delayed in its search for a Covid vaccine.
PHASE 3 REMDESIVIR TRIAL SHOWS PROMISING SIGNS OF SUCCESS – Gilead’s antiviral drug Remdesivir has shortened the average recovery time for Covid-19 in the largest of several recent trials. Weak evidence also shows that the drug reduces death in patients. The U.S. director of NIAID hailed the drug as the ‘standard of care’. It allegedly reduced average time to recover by 31% over those taking a placebo. This comes as five hospitals in Australia are set to receive doses of the sought-after drug. The only confirmed hospital so far is St Vincent’s hospital in Sydney.
PFIZER PREPARING FOR U.S. COVID-19 TRIALS NEXT WEEK – Pfizer will begin clinical trials of mRNA-based Covid candidate BNT162 in America next week, the company announced. The product has already undergone phase 1 and 2 trials in Germany, with FDA approval expected ‘shortly’. The company is expecting to manufacture millions of doses of the drug by the end of 2020.
HIGH-DOSE CHLOROQUINE TRIAL STOPPED OVER RAISED DANGER OF DEATH – A study of chloroquine, a drug similar to anti-malaria treatment hydroxychloroquine, has been stopped after high-dose patients showed a higher death rate than those who took low doses of the drug. High-dose patients also showed higher incidences of toxicity, though elements of the study meant researchers could not determine the independent toxicity of high-dose chloroquine.
In other news:
R&D
Natural killer cell therapies show promise for fighting cancer
Clinical Trials
GSK has delayed most of its non-Covid-19 clinical trials
UK’s ACCORD-2 pharma collaboration looks to cut Covid-19 drug development to a few weeks
AiCure releases ‘digital biomarker’ app for clinical trials
Manufacturing
AstraZeneca partners with Oxford University to produce potential vaccine
J&J and Catalent sign deal over Covid-19 vaccine manufacturing
That’s all for now. See you next week!
Joshua Neil, Editor
Proventa International
To ensure you remain up-to-date on the latest in clinical development, sign up for Proventa International’s online Clinical Operations, Supply Chain & Pharmacovigilance Strategy Meeting 2020.
RNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years agoRNA Therapeutics: The World’s First mRNA Malaria Vaccine
Malaria represents one of the greatest unmet clinical needs in the world. In the last decade, research has been ongoing to develop effective preventative methods and effective treatment to reduce the risk of severe illness, which typically occurs in children....
2 years ago
Raising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years agoRaising Representation in Clinical Trials: An Interview with Liz Beatty, Inato
The COVID-19 pandemic created a significant shortage of suitable patients for clinical trials worldwide. Within this crisis was another more serious issue around inclusion and representation, driven by COVID’s disparate effect on certain ethnicities, that spoke to a wider issue...
2 years ago
Intrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets
Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...
2 years agoIntrinsically Disordered Proteins – The Implication in Cancer and Potential Drug Targets
Intrinsically disordered proteins (IDPs) are under the limelight in cancer research. While research is continuous in understanding their dynamic structure, their implication in tumour development is becoming increasingly evident. Some of the latest advancements demonstrate how IDPs can be used...
2 years ago